Zhongguo aizheng zazhi (Jul 2023)
Research progress on thyroid dysfunction induced by immunotherapy for lung cancer
Abstract
Immune checkpoint inhibitors [mainly programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors] have emerged as the most promising therapy in lung cancer treatment. However, clinicians still lack sufficient knowledge about immune-related adverse events. Immune-related thyroid dysfunction (irTD), one of the common immune-related adverse events, can be life-threatening in severe cases. This article discussed the thyroid dysfunction induced by PD-1/PD-L1 inhibitors in the treatment of lung cancer from the aspects of the incidence, pathogenesis, predictive biomarkers and treatment of irTD.
Keywords